What we have learned from the Optic Neuritis Treatment Trial.
Beck
R W
RW
Jaeb Center for Health Research, Inc., Tampa, FL 33613, USA.
Trobe
J D
JD
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D009902:Optic Neuritis / Q000188:drug therapy* / Q000503:physiopathology; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
D000893:Anti-Inflammatory Agents; D008776:Methylprednisolone Hemisuccinate; D011239:Prednisolone